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During the past several decades, the efforts of cancer 
immunotherapy have been focused on identifying specific 
tumor antigens to augment antitumor immunity. However, 
this approach has been constantly challenged by the 
complexity and diversity of gene mutations and protein 
modification present in human cancers as well a complex 
tumor microenvironment, resulting in limited or failed 
therapeutic success (1-3). Recently discovered immune 
checkpoint pathways, including programmed death 
receptor 1/programmed death ligand 1 (PD-1/PD-L1) 
signaling pathway, were shown to protect host from 
overactive T-effector cells not only in cancer but also 
during microbial infections (4,5). PD-1 is preferentially 
expressed on activated T-cells with particularly high 
expression in the population of tumor-infiltrating T-cells, 
while PD-L1, one of its key ligands, has been found to be 
overexpressed (activated) in various solid malignancies, 
most notably in malignant melanoma, non-small cell lung 
carcinoma (NSCLC), renal cell carcinoma, advanced 
urothelial carcinoma and various solid cancers exhibiting 
high mutational load and/or microsatellite instability 
(MSI-H) (2,6,7). PD-L1 activation has also been described 
in hematologic malignancies, such as multiple myeloma, 
both non-Hodgkin and Hodgkin lymphomas (most notable 
in classical Hodgkin lymphoma), some leukemias as well as 
systemic histiocytoses (3,8-10).
Development of therapeutic antibodies that inhibit 
PD-1/PD-L1 pathway (immune checkpoint inhibitors) 
seems to be a promising tool in terms of clinical benefits 
and overall patients’ survival (11). However, cancer cells 
frequently manipulate PD-1/PD-L1 axis to evade immune 
surveillance (3,12). Therefore, only a subset of patients 
respond to these agents and fewer still achieve a durable 
response (11).
Among the well-known mechanisms that lead to 
unresponsiveness to anti-PD1/PD-L1 therapy are loss-of-
function mutations in Janus kinase 1/2 (JAK1/2) genes (13). 
A key functional result from somatic JAK1/2 mutations 
in cancer cells is the inability to respond to interferon 
gamma (INF-ᵞ) by overexpressing PD-L1 and many other 
interferon-stimulated genes (e.g., IFNGR1, TYK2, STAT1, 
Stat3, IRF1) (13). Patients with such burden would be 
unlikely to respond to PD-1/PD-L1 blockade therapy 
(14,15). 
Other pathways and regulators have also been found to 
upregulate PD-L1 in cancer cells including PTEN-PI3K-
AKT pathway, ALK, STAT3, HDAC6, interleukins 4 and 10, 
vascular endothelial growth factor (VEGF), granulocyte 
colony-stimulating factor (G-CSF) and bacterial IF-ɣ 
lipopolysaccharide (3). However, INF-ɣ appears to be a key 
regulator (16,17).
Understanding the mechanisms contributing to an 
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effective response and resistance are of utmost importance 
to optimize treatment with immune checkpoint inhibitors 
(11,18). In this context, two potential pathways (CMTM6 
and CMTM4), considered as PD-L1 regulators, have been 
recently discovered in maintaining antitumor immunity 
(19,20).
Burr et al. and Mezzadra et al. independently identified 
CKLF-like MARVEL transmembrane domain containing 
protein 6 (CMTM6) using CRISPR-Cas9 deletion library 
screen (19,20). CMTM6 is a ubiquitously expressed protein 
with previously unknown function; it appears to play a 
role in limiting antitumor immunity. CMTM6 belongs 
to a family of proteins, primarily encoded by two distinct 
gene clusters located on chromosome 16 (CMTM1–4) 
and chromosome 3 (CMTM6–8). MARVEL domain 
proteins have been implicated in regulating trafficking of 
transmembrane and secretory proteins (19). Depletion 
of CMTM6 led to a marked reduction of PD-L1 protein 
level, but not its transcriptional levels. Levels of MHC I 
and PD-L2 were not significantly affected by CMTM6 
inhibition, indicating that although CMTM6 regulated 
PD-L1 at the protein level, it is not a general regulator 
of protein translation or stability (20). Interestingly, most 
common PD-L1 up-regulator INF-ɣ was not correlated 
with CMTM6 pathway.
A close family member CMTM4 with 55% homology to 
CMTM6 was identified to share this function in CMTM6-
deficient HAP1 cells, but not any other CMTM member. 
CMTM4 is considered as a back-up regulator of PD-L1 
expression (20).
Among all proteins upon cell surface, only small number 
of high-confidence proteins are interacting with CMTM6. 
PD-L1 was one of the top ranked. CMTM6 is established 
as a new regulatory target to specifically vary the cell 
surface expression of this critical immune checkpoint 
molecule. Although CMTM6 is found within cytosol and 
plasma membrane, it is not required for the trafficking 
of PD-L1 from the endoplasmic reticulum to the cell 
surface, but is required for stable expression of PD-L1 at 
the cell membrane (19,20). CMTM6-deficient tumor cells 
were also more susceptible to antigen-specific cytotoxic 
T-lymphocytes in vitro and were associated with longer 
survival in a murine transplantable melanoma model.
Another interesting observation from these studies is 
that CMTM6 protects PD-L1 from ubiquitination and 
helps it be recycled and evade lysosomal degradation (19). 
Also, STUB1, an E3 ubiquitin ligase, has been identified as 
a negative regulator of PD-L1. Deletion of STUB1 resulted 
in a stronger increase in PD-L1 levels in CMTM6-deficient 
than in CMTM6-proficient cells (20). 
Although several questions are yet to be addressed (e.g., 
how to translate these findings into therapeutics, potential 
adverse side effects), CMTM6 is surely an important player 
in the tumor microenvironment and antitumor immunity. 
CMTM6 was found to be a key regulator of T lymphocyte-
mediated anti-tumor immunity, in diseases that respond to 
immune checkpoint inhibitors through modulation of the 
PD-L1 expression ex vivo (in humans) and in vivo (mouse), 
respectively (19). Further basic and translational studies 
should confirm these findings and enable novel approaches 
to enhance the effectiveness and clinical benefits of the 
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